Loading...

Precipio, Inc.

PRPO•NASDAQ
HealthcareMedical - Diagnostics & Research
$8.98
$0.61(7.29%)

Precipio, Inc. (PRPO) Stock Overview

Explore Precipio, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
5.05%
↑ 5.05%
Profit Growth
$-2.06
↑ 26.70%
EPS Growth
$-2.06
↑ 35.03%
Operating Margin
-15.50%
↑ 44.67%
ROE
-25.87%
↑ 26.70%
Dividend Yield
0.00%
Analyst Recommendations data is not available for PRPOAnalyst Recommendations details for PRPO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

CEO

Mr. Ilan Danieli

Employees

54

Headquarters

4 Science Park, New Haven, CT

Founded

2017

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.